JOP20220033A1 - نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات - Google Patents

نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات

Info

Publication number
JOP20220033A1
JOP20220033A1 JOP/2022/0033A JOP20220033A JOP20220033A1 JO P20220033 A1 JOP20220033 A1 JO P20220033A1 JO P20220033 A JOP20220033 A JO P20220033A JO P20220033 A1 JOP20220033 A1 JO P20220033A1
Authority
JO
Jordan
Prior art keywords
delivery
antiviral agents
drug delivery
delivery system
drug
Prior art date
Application number
JOP/2022/0033A
Other languages
English (en)
Inventor
Koynov Athanas
S Teller Ryan
Elizabeth BARRETT Stephanie
P Forster Seth
B Giles Morgan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of JOP20220033A1 publication Critical patent/JOP20220033A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

يتعلق هذا الاختراع بأنظمة جديدة لتوصيل الأدوية المزروعة من أجل التوصيل طويل المفعول للأدوية المضادة للفيروسات. تعتبر هذه التركيبات مفيدة في علاج أو الوقاية من عدوى فيروس نقص المناعة البشرية (HIV).
JOP/2022/0033A 2019-08-13 2020-08-11 نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات JOP20220033A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885968P 2019-08-13 2019-08-13
PCT/US2020/045693 WO2021030306A1 (en) 2019-08-13 2020-08-11 Drug delivery system for the delivery of antiviral agents

Publications (1)

Publication Number Publication Date
JOP20220033A1 true JOP20220033A1 (ar) 2023-01-30

Family

ID=74570758

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0033A JOP20220033A1 (ar) 2019-08-13 2020-08-11 نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات

Country Status (18)

Country Link
US (1) US20220362277A1 (ar)
EP (1) EP4013407A4 (ar)
JP (1) JP7317210B2 (ar)
KR (1) KR20220047307A (ar)
CN (1) CN114206336A (ar)
AU (1) AU2020328518A1 (ar)
BR (1) BR112022002386A2 (ar)
CA (1) CA3150272A1 (ar)
CL (1) CL2022000318A1 (ar)
CO (1) CO2022001356A2 (ar)
CR (1) CR20220053A (ar)
DO (1) DOP2022000036A (ar)
EC (1) ECSP22010042A (ar)
IL (1) IL290421A (ar)
JO (1) JOP20220033A1 (ar)
MX (1) MX2022001765A (ar)
PE (1) PE20220707A1 (ar)
WO (1) WO2021030306A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012768A (es) * 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
RU2755130C2 (ru) * 2016-05-12 2021-09-13 Мерк Шарп И Доум Корп. Система доставки лекарств для доставки противовирусных средств
US11419817B2 (en) * 2017-04-10 2022-08-23 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
KR20210105931A (ko) * 2018-12-20 2021-08-27 머크 샤프 앤드 돔 코포레이션 Nrtti 화합물의 신규 결정질 형태

Also Published As

Publication number Publication date
EP4013407A4 (en) 2023-08-23
CR20220053A (es) 2022-04-20
BR112022002386A2 (pt) 2022-04-26
PE20220707A1 (es) 2022-05-04
MX2022001765A (es) 2022-03-17
CL2022000318A1 (es) 2022-10-07
CN114206336A (zh) 2022-03-18
EP4013407A1 (en) 2022-06-22
CA3150272A1 (en) 2021-02-18
AU2020328518A1 (en) 2022-03-10
CO2022001356A2 (es) 2022-03-18
DOP2022000036A (es) 2022-03-31
IL290421A (en) 2022-04-01
JP2022546755A (ja) 2022-11-08
JP7317210B2 (ja) 2023-07-28
WO2021030306A1 (en) 2021-02-18
KR20220047307A (ko) 2022-04-15
ECSP22010042A (es) 2022-03-31
US20220362277A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2018013662A (es) Sistema de entrega de farmacos para la entrega de agentes antivirales.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MD20220043A2 (ro) Compuşi foarte activi împotriva COVID-19
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
MX2012007410A (es) Compuestos antivirales novedosos.
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MX2022002897A (es) Profarmacos antivirales y formulaciones de los mismos.
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
WO2007013047A3 (en) Water-dispersible anti-retroviral pharmaceutical compositions
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MY168784A (en) The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
MX2022001765A (es) Sistema de administracion de medicamentos para la administracion de agentes antiviricos.
CR20220418A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
MX2022013759A (es) Sistema de suministro de farmacos para el suministro de agentes antivirales y contraceptivos.
MX2022006940A (es) Composiciones farmaceuticas.
MX2023008004A (es) Derivado de adenosina y composicion farmaceutica que lo comprende.
JOP20220188A1 (ar) عوامل مضادة للفيروسات لعلاج عدوى فيروس نقص المناعة البشرية والوقاية منها
MX2019013819A (es) Oligopeptidos inhibitorios de la angiogenesis y de la funcion vascular.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.